Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine?

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSILVA, Lais Teodoro da
dc.contributor.authorPONTILLO, Alessandra
dc.contributor.authorSILVA, Wanessa Cardoso da
dc.contributor.authorALMEIDA, Alexandre de
dc.contributor.authorDUARTE, Alberto Jose da Silva
dc.contributor.authorOSHIRO, Telma Miyuki
dc.date.accessioned2014-01-28T22:27:10Z
dc.date.available2014-01-28T22:27:10Z
dc.date.issued2013
dc.description.abstractAims: HIV-1 expanded in an allogenic system (Al-HIV) represents a cheaper and faster alternative to the autologous virus (Au-HIV) as an antigen in anti-HIV immunotherapy. In this study, chemically inactivated HIV-1 obtained through autologous or allogenic systems were compared. Patients & methods: Au-HIV and Al-HIV obtained from cultures of peripheral blood mononuclear cells from 11 HIV+ individuals were tested for virus production, yield and time of culture, and their ability to elicit a specific immune response in vitro. Results: The allogenic system was more efficient than the autologous system. Dendritic cells pulsed with Au-HIV and Al-HIV presented a similar phenotypic profile, but only Al-HIV induced a significant increase in IFN-(+) lymphocytes. Conclusion: The use of an allogenic system displays several advantages in terms of cell manipulation, time and cost of culture, and immunogenicity.
dc.description.indexMEDLINE
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP [2012/18879-6]
dc.identifier.citationIMMUNOTHERAPY, v.5, n.12, p.1305-1311, 2013
dc.identifier.doi10.2217/imt.13.136
dc.identifier.issn1750-743X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/4282
dc.language.isoeng
dc.publisherFUTURE MEDICINE LTD
dc.relation.ispartofImmunotherapy
dc.rightsrestrictedAccess
dc.rights.holderCopyright FUTURE MEDICINE LTD
dc.subjectautologous HIV
dc.subjectdendritic cell
dc.subjecttherapeutic vaccine
dc.subjectvirus production
dc.subject.othercell-based vaccine
dc.subject.otherdendritic cells
dc.subject.otherinfection
dc.subject.othervirus
dc.subject.otherimmunization
dc.subject.wosImmunology
dc.titleAutologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine?
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus1
hcfmusp.contributor.author-fmusphcLAIS TEODORO DA SILVA
hcfmusp.contributor.author-fmusphcALESSANDRA PONTILLO
hcfmusp.contributor.author-fmusphcWANESSA CARDOSO DA SILVA
hcfmusp.contributor.author-fmusphcALEXANDRE DE ALMEIDA
hcfmusp.contributor.author-fmusphcALBERTO JOSE DA SILVA DUARTE
hcfmusp.contributor.author-fmusphcTELMA MIYUKI OSHIRO SUMIDA
hcfmusp.description.beginpage1305
hcfmusp.description.endpage1311
hcfmusp.description.issue12
hcfmusp.description.volume5
hcfmusp.origemWOS
hcfmusp.origem.pubmed24283841
hcfmusp.origem.scopus2-s2.0-84889566570
hcfmusp.origem.wosWOS:000327426800012
hcfmusp.publisher.cityLONDON
hcfmusp.publisher.countryENGLAND
hcfmusp.relation.referenceBrenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
hcfmusp.relation.referenceConnolly NC, 2008, CLIN VACCINE IMMUNOL, V15, P284, DOI 10.1128/CVI.00221-07
hcfmusp.relation.referenceGarcia F, 2005, J INFECT DIS, V191, P1680, DOI 10.1086/429340
hcfmusp.relation.referenceGarcia F, 2013, SCI TRANSL MED, V5
hcfmusp.relation.referenceGarcia F, 2011, J INFECT DIS, V203, P473, DOI 10.1093/infdis/jiq077
hcfmusp.relation.referenceGil C, 2011, VACCINE, V29, P5711, DOI 10.1016/j.vaccine.2011.05.096
hcfmusp.relation.referenceKundu SK, 1998, AIDS RES HUM RETROV, V14, P551, DOI 10.1089/aid.1998.14.551
hcfmusp.relation.referenceLu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
hcfmusp.relation.referenceRossio JL, 1998, J VIROL, V72, P7992
hcfmusp.relation.referenceSabado RL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004256
hcfmusp.relation.referenceWhiteside TL, 2009, CLIN VACCINE IMMUNOL, V16, P233, DOI 10.1128/CVI.00066-08
hcfmusp.relation.referenceWHO, 2002, WHO UNAIDS GUID STAN
hcfmusp.remissive.sponsorshipFAPESP
hcfmusp.scopus.lastupdate2024-06-16
relation.isAuthorOfPublication76678ebb-9a2f-4da3-96a1-89f921d54050
relation.isAuthorOfPublication7e4d82b9-e241-48a9-8ff4-df644d6d9b55
relation.isAuthorOfPublication4bddbc52-0121-4867-a3d4-89799ea780b3
relation.isAuthorOfPublication48ca2960-f9d4-42ca-aba3-d7fbfd970a4e
relation.isAuthorOfPublication8e4f2c15-06a5-444b-826d-84576403144e
relation.isAuthorOfPublicationc11d37d4-87f0-4747-910f-14b550a91438
relation.isAuthorOfPublication.latestForDiscovery76678ebb-9a2f-4da3-96a1-89f921d54050
Arquivos